Study on GBM for non-viral delivery therapy of antiangiogenic factors

Anne Clavreul of neurosurgery at the University of Ange in France uses non-viral methods such as enhanced delivery devices (CED devices), implantable polymer devices, nanocarriers or cell vectors to enable angiogenesis inhibitors to perform anti-tumor angiogenesis in intracranial insinuate GBM animal modelsThe findings were published in the April 2019 Issue of International Journal of Nanomedicine- From the articleRef:Clavreul A,et al.
Int J Nanomedicine.2019 Apr 9;14:2497-2513doi: 10.2147/IJNS194858eCollection 2019The emergence of angiogenesis inhibitors, such as vascular endothelial growth factor (VEGF) inhibitors, has given new light to the treatment of GBMBut so far, no Phase III clinical trial has found that angiogenesis inhibitors have more survival benefitsCurrently, researchers are trying to find new angiogenesis inhibitors and deliver them by virus or non-viral, improving the effectiveness of antiangiogenic activity and inhibiting angiogenesisAnne Clavreul of neurosurgery at the University of Ange in France uses non-viral methods such as enhanced delivery devices (CED devices), implantable polymer devices, nanocarriers or cell vectors to enable angiogenesis inhibitors to perform anti-tumor angiogenesis in intracranial insinuate GBM animal models The findings were published in the April 2019 Issue of International Journal of Nanomedicine there are five mechanisms for increasing GBM blood supply: the body's blood vessels are increased through the existing vasculature system, the tumor cells are captured during the invasion of the tumor cells, the dilation and branching of tumor blood vessel formation, the tumor stem cell-like cells differentiate into the tumor vascular endothelial cells and bone marrow source of vascular endothelial cell production (Figure 1) Figure 1 The mechanism of GBM and tumor vascular production Note: ePCs: endothelial progenitor cells; GB: glioblastoma; GSCs: glioblastoma stem cell-like cells; HSC: hematopoietic stem cells; MSCs: interstitial stem cells or interstitial matrix cells tumor angiogenesis plays an important role in the progression of GBM, so the development of new angiogenesis inhibitors is an important research topic to conquer GBM There are four types of angiogenesis inhibitors clinically used in GBM treatment trials: endogenous factors, monoclonal antibodies, tyrosine kinase inhibitors, and other factors (Figure 2) Figure 2 GBM and angiogenesis inhibitors Notes: GBM: glioblastoma; HeR2:eGF-related receptor 2; IFN: interferon; MeT: hepatocellular growth factor receptor; PEX: matrix metalloproteinase-2 fragment; PF-4: platelet factor-4; TSP: platelet reactive protein There are four methods of non-viral transmission angiogenesis factor, including enhanced delivery devices (CED devices), implantable polymer devices, nanocarriers or cell vectors (Figure 3 ); figure 3 Non-viral delivery of antiangiogenic factors Notes: CED: Enhanced Delivery; CPP: 3-Double-Toxyloxypropane; GBM: Glioblastoma; LNCs: Lipid Nanocapsules; MSCs: Interstinator Stem Cells; NSCs: Neurostem Cells; PLGA: Polypropylene-Ethyl; SA: Dyscocte finally the authors believe that the results of the system shown in Figure 4 in the preclinical model of GBM should be monitored to determine its specific efficacy Figure 4 Antiangiogenic Factor Delivery Methods and Clinical Transformation Practices.